PRESS RELEASE
Ergomed expands operations in Japan
N ew legal entity and regional office established in Tokyo respond ing to client demand
Guildford , UK – 26 April 2 021 : Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that its PrimeVigilance business, a global leader in the provision of pharmacovigilance and medical information services, has established its new legal entity and regional office in Japan and is fully operational from 26 April 2021.
The new subsidiary company, trading as PrimeVigilance Japan KK, is based in Tokyo and offers a comprehensive range of pharmacovigilance services, including a dedicated Japanese safety database. Full Japanese language Medical Information services are also provided.
This expansion provides existing and prospective international PrimeVigilance clients the opportunity to extend their product coverage into the strategically important Japanese pharmaceutical market, the fourth largest globally after the US, the EU and China. It also provides PrimeVigilance and Ergomed the opportunity to provide high quality specialist services to domestic Japanese companies, opening up a new market.
PrimeVigilance has a strong operational presence in Europe and the recent acquisitions of Ashfield PV and MedSource, as well as significant organic growth in the US, have elevated PrimeVigilance into a market leading position in North America. The new facility in Japan adds Asia to Ergomed’s global footprint, enabling PrimeVigilance to offer operational services in all major regions, with pharmacovigilance and medical information professionals based in each territory, providing both local and global expertise.
Dr Miroslav Reljanovic , Executive Chairman of Ergomed, said : “ Ergomed has provided a breadth of service s and expertise in Asia both as a CRO and as a pharmacovigilance specialist through its outsourcing model for many years . With a solid bas e of international clients in Japan , Ergomed is establishing its own pharmacovigilance and medical information infrastructure to serve current and future clients and further strengthen our global operational and commercial footprint in the strategica lly importan t Asia region . F ollowing the two US acquisitions in 2020 of Ashfield Pharmacovigilance (now PrimeVigilance USA) and MedSource , this marks another major step in our strategy to establish Ergomed as a leading international pharmaceutical services s pecialis t .”
ENDS
Enquiries:
| Ergomed plc |
Tel: +44 (0) 1483 402 975 |
| Miroslav Reljanovic (Executive Chairman) |
|
| Richard Barfield (Chief Financial Officer) |
|
|
|
| Numis Securities Limited |
Tel: +44 (0) 20 7260 1000 |
| Freddie Barnfield / Matthew O’Dowd (Nominated Adviser) |
|
| James Black (Broker) |
|
|
|
| Consilium Strategic Communications |
Tel: +44 (0) 20 3709 5700 |
| Chris Gardner / Matthew Neal |
ergomed@consilium-comms.com |
| Olivia Manser / Angela Gray |
|
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical trials, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes a full range of high-quality contract research and clinical trial management (CRO) services under the Ergomed brand together with an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and an internationally recognized specialist expertise in orphan drug development, under the PSR brand. For further information, visit: http://ergomedplc.com .
